2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre C
Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Biological Therapies, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

315 Evaluation of real-world effectiveness and safety outcomes for lisocabtagene maraleucel (liso-cel) and bispecific antibodies (BsAb) in second-line (2L) relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Narendranath Epperla, MD, MS, FACP, Paolo Fabrizio Caimi, MD2, Jennifer J. Huang, MD, PhD3, Farah Toron, MSc, BSc4, David Bernasconi5, Robert Braun, MD, MBA6, Fei Fei Liu, GDCE, MBA7, Sagar S Patel, MD8, Nathan Denlinger, DO, MS9
1 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
2 CCF Taussig Cancer Center, Cleveland, Ohio, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Bristol Myers Squibb, Uxbridge, United Kingdom
5 Bristol Myers Squibb, Boudry, Switzerland
6 Bristol Myers Squibb, Boudry, Switzerland
7 Bristol Myers Squibb, Princeton, New Jersey, United States
8 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Introduction: Liso-cel and CD3×CD20 T-cell engaging BsAb are approved therapies for LBCL in the United States (US). Understanding how emerging treatments (tx) for patients (pts) with LBCL compare with liso-cel, an established 2L tx option, will inform evidence-based decision-making in clinical practice. This study compared real-world effectiveness and safety of liso-cel and BsAb in pts with 2L R/R LBCL.

Methods: Pts with 2L R/R LBCL who started tx with liso-cel or BsAb (epcoritamab or glofitamab) in routine clinical practice (index date, 05/2023–12/2025) were identified from the Flatiron Health Research Database (FHRD). The FHRD collects longitudinal data for US pts treated at academic medical centers and community oncology practices. Effectiveness outcomes were OS, PFS, time to next tx (TTNT), CR rate, and ORR. Safety outcomes were cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), prolonged cytopenia, and infections. Inverse probability of tx weighting methods were used to balance characteristics between cohorts (eg, bulky disease [mass of ≥5 cm], high-grade B-cell lymphoma, ECOG PS, and LDH). A sensitivity analysis was conducted in pts who received ≥3 doses of BsAb and reached the target dose (epcoritamab, 48 mg; glofitamab, 30 mg).

Results: Of 301 pts, 229 received liso-cel and 72 received BsAb; median age at index was 71 y (IQR, 62–76) and 71.5 y (IQR, 62.5–78.5), respectively (P=0.271). The median follow-up was 15.7 mo for liso-cel and 8.5 mo for BsAb. Most pts had DLBCL, not otherwise specified (liso-cel, 83%; BsAb, 78%) and had bulky disease (liso-cel, 69%; BsAb, 79%; P=0.083); 24% and 47% had elevated LDH, respectively (P<0.001). Before tx, ECOG PS was 0–1 for 84% (147/175) in the liso-cel cohort and 67% (39/58) in the BsAb cohort (P=0.006). Among BsAb-treated pts, 40% received BsAb as monotherapy and 60% in combination-based regimens.

The liso-cel cohort had significantly longer OS (unadjusted HR, 0.32, P<0.001; adjusted HR, 0.48, P=0.003) and PFS (unadjusted HR, 0.42, P<0.001; adjusted HR, 0.58, P=0.007) than BsAb; 6-mo adjusted OS rates were significantly higher with liso-cel (89% vs 70%; P=0.001), and PFS rates were 66% versus 52% (P=0.062), respectively. The liso-cel cohort had significantly longer TTNT than the BsAb cohort (unadjusted HR, 0.44, P<0.001; adjusted HR, 0.58, P=0.007), with 6-mo adjusted TTNT rates of 67% with liso-cel and 55% with BsAb (P=0.113). CR rate was significantly higher in the liso-cel cohort (unadjusted, 64% vs 32%, P<0.001; adjusted, 63% vs 33%, P<0.001) than BsAb; ORR was similar between cohorts after adjustment (79% vs 73%; P=0.390; unadjusted, 79% vs 66%, P=0.04).

There was no statistical difference in the adjusted rate of any-grade CRS between liso-cel and BsAb (34% vs 45%; P=0.069). However, grade ≥3 CRS occurred significantly less frequently with liso-cel than BsAb (0% vs 6%; P<0.001). There was no statistical difference in any-grade ICANS rate between liso-cel and BsAb (19% vs 16%; P=0.606) or grade ≥3 ICANS (3% vs 7%; P=0.158). Rates of prolonged cytopenia (21% vs 28%; P=0.272) and infections (8% vs 10%; P=0.653) were similar for liso-cel and BsAb.

In a sensitivity analysis (unadjusted) of pts who received ≥3 doses of BsAb and reached the target dose (BsAb, n=63), liso-cel was associated with significantly longer OS (HR, 0.32; P<0.001) and PFS (HR, 0.43; P<0.001). ORR was similar between cohorts (79% vs 78%; P=0.822), whereas CR rate was significantly higher with liso-cel than BsAb (64% vs 38%; P=0.001). In safety analyses, rates of any-grade CRS for liso-cel and BsAb were not statistically different (32% vs 21%; P=0.073), while grade ≥3 CRS occurred significantly less frequently with liso-cel than BsAb (0% vs 3%; P=0.008). The rate of any-grade ICANS was also not statistically different between liso-cel and BsAb (17% vs 10%; P=0.144); grade ≥3 ICANS were experienced by 3% of pts in each cohort (P=0.864). Prolonged cytopenia (21% vs 22%; P=0.769) and infections (8% vs 5%; P=0.346) occurred at similar frequencies for liso-cel and BsAb.

Conclusions: In this real-world analysis of pts with 2L R/R LBCL, liso-cel was associated with significantly improved OS, PFS, TTNT, deep and durable response with high CR rates, and lower incidence of grade ≥3 AEs compared with BsAb. These findings suggest improved outcomes and favorable safety with liso-cel over BsAb, further supporting liso-cel as an effective tx option in the 2L setting.

Narendranath Epperla, MD, MS, FACP: CRISPR Therapeutics - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Ipsen - Research Funding; Incyte - Research Funding; ADC Therapeutics - Research Funding; ADC Therapeutics - Research Funding; Eli Lilly - Research Funding; Genetech - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)